Loading
CATNON showed that a year of temozolomide after radiotherapy lengthens survival in anaplastic gliomas that lack the 1p/19q co-deletion, and that the benefit is concentrated in IDH-mutant tumours.
CATNON randomised 751 adults with newly diagnosed 1p/19q non-co-deleted anaplastic glioma in a two-by-two design to radiotherapy alone, with concurrent temozolomide, with 12 cycles of adjuvant temozolomide, or both. Adjuvant temozolomide improved overall survival (hazard ratio 0.65 in the interim analysis; five-year survival 55.9 vs 44.1 percent), while concurrent temozolomide did not in the tumours as a whole and helped only IDH-mutant tumours (van den Bent and colleagues, Lancet 2017 and Lancet Oncology 2021).
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
751 enrolled.
Interim analysis after 219 deaths, 745 patients enrolled; hazard ratio 0.65 with 99.145% CI 0.45-0.93
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survival at 5 yearsprimary | Adjuvant temozolomide | - | 55.9% | 0.65 | - | link |
| No adjuvant temozolomide | - | 44.1% |
Shares Brain and spinal cord tumours (all types), IMRT / IGRT (modern external beam) and the tag radiation-wave2.
Shares Chemoradiation (chemoradiotherapy, CRT), IMRT / IGRT (modern external beam) and the tag radiation-wave2.
Shares Brain and spinal cord tumours (all types) and the tag radiation-wave2.
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave2.
Shares Brain and spinal cord tumours (all types) and the tag radiation-wave2.
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave2.
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave2.
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave2.